|Articles|March 2, 2023
- Pharmaceutical Technology, March 2023
- Volume 47
- Issue 3
- Pages: 12
CHO-Based Assay Kit
Charles River’s HCP-ELISA kit is designed to increase the efficiency and efficacy of HCP assay development.
Charles River Laboratories’ enzyme-linked immunosorbent assay (ELISA) kit is designed for the detection and quantitation of residual host cell proteins (HCP) in Chinese hamster ovary (CHO)-based biotherapeutics. Building on the company’s HCP-GAPex service, the HCP–ELISA kit is designed to increase the efficiency and efficacy of HCP assay development.
The HCP–ELISA kit has a 96-well assay plate and has a time-to-result of approximately three hours. It leverages avian immunoglobulin Y antibodies as the primary detection technology, which are derived from specific-pathogen-free chicken eggs developed exclusively by AVS Bio.
Articles in this issue
over 2 years ago
Harnessing Technology to Ensure Drug Safetyover 2 years ago
Excipients Impact Stability in mRNA-LNP Formulationsover 2 years ago
Influencing Change in Drug Deliveryover 2 years ago
Frontrunner in Microbiome Therapeuticsover 2 years ago
Implementing Process Analytical Technologyover 2 years ago
Taking Steps Toward Supply Chain Continuityover 2 years ago
Keeping Europe’s Medicines StockedNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Thermo Fisher Launches OpenAI Partnership at CPHI Frankfurt 2025: Part One
2
Sustainability and Stability in Excipients
3
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
4
Takeda Talks at CPHI Frankfurt 2025 About Smart Pharma Packaging Impacts
5
